Sign up for OUR newsletter
The latest news from Invest in OdenseStay Informed with the Latest Business News and Events from Invest in Odense
Subscribe to our newsletter and receive the most recent updates directly in your inbox. Make sure to choose the areas of your interest to get information that is most relevant for you.
We are dedicated to bringing you exciting updates from a business perspective, ensuring you stay ahead in the dynamic business environment of Odense.
The newsletter from Invest In Odense is issued regularly throughout the year, keeping you updated on the evolving business landscape in the city.
Register now using the form below
Latest articles about business in Odense
Odense takes the lead: 14 Million DKK to Boost Competencies in the Life Science Sector
With a fresh injection of 14 million DKK UCL University College is set to transform Denmark’s life science sector by placing Odense firmly on the map as the nation’s innovation powerhouse. As the coordinating hub for a nationwide upskilling initiative, Odense is sending a clear signal to international investors: this is where the future of life science is being shaped.
Global investment meets Odense innovation – Evosep enters a new era in clinical proteomics
With Nordic Capital as majority shareholder, Evosep strengthens its global position – and Odense’s role as a rising life science city. The recent acquisition of Evosep by Nordic Capital marks the biggest direct life science exit in EIFO history. It’s a clear signal that Denmark is not just participating in the global health innovation race – we’re building companies that can lead it.
Inverna Therapeutics Receives Major Grant from the Michael J. Fox Foundation to Boost Parkinson’s Research
Inverna Therapeutics has been awarded a USD 700,000 research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), one of the world’s leading supporters of Parkinson’s innovation. The funding will help advance Inverna’s next-generation RNA therapy, a new approach aimed at slowing or stopping the progression of Parkinson.